Elsevier Announces the Anxiety and Depression: 21st Neuropharmacology Conference

OXFORD, England, March 9, 2011 - Elsevier, the leading publisher of scientific, technical and medical
information products and services, today announced that the Anxiety and
Depression: 21st Neuropharmacology Annual Conference will take place in
Virginia, USA on 10-11 November 2011 as a satellite to the 2011 Meeting of
the Society for Neuroscience.

Anxiety and depression are amongst the most common brain disorders, with
significant consequences for the individual and society. The 21st
Neuropharmacology annual conference will bring together the leading experts
in the field of psychiatry, neuroscience and pharmacology to present and
discuss the latest research.

The scientific committee composed of acknowledged opinion leaders in
anxiety and depression from across the spectrum of research areas will work
alongside organizers from Elsevier to develop a multidisciplinary programme.

"The 21st Neuropharmacology Conference on Anxiety and Depression provides
researchers with a marvelous opportunity to share knowledge and network with
their peers," said Michael Osuch, executive publisher at Elsevier.

    Among the topics covered at the Anxiety and Depression Conference are:

    - Emerging Therapeutic Targets in Depression
    - Emerging Therapeutic Targets in Anxiety
    - Animal Models
    - Genetics and Epigenetics in Depression and Anxiety
    - Imaging
    - Developmental Aspects of Anxiety and Depression
    - Neuronal Circuits Underlying Anxiety and Depression
    - Fear Extinction
    - Mechanism of Action of Antidepressants and Anxiolytics

Attendees are welcome to register at:

www.neuropharmacology-conference.elsevier.com

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and
medical information products and services. The company works in partnership
with the global science and health communities to publish more than 2,000
journals, including The Lancet (www.thelancet.com/) and Cell
(www.cell.com/), and close to 20,000 book titles, including major
reference works from Mosby and Saunders. Elsevier's online solutions include
SciVerse ScienceDirect (www.sciencedirect.com/), SciVerse Scopus
(www.scopus.com/), Reaxys (https://www.reaxys.com/info/), MD Consult
(www.mdconsult.com/) and Nursing Consult (
www.nursingconsult.com/), which enhance the productivity of science
and health professionals, and the SciVal suite (www.scival.com/) and
MEDai's Pinpoint Review (www.medai.com/), which help research and
health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier (
www.elsevier.com/wps/find/homepage.cws_home) employs 7,000 people
worldwide. The company is part of Reed Elsevier Group PLC (
www.reedelsevier.com/), a world-leading publisher and information
provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV.
The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange),
RUK and ENL (New York Stock Exchange).

    Media Contact

    Francesca Webb
    +44(0)1865-843244
    f.webb@elsevier.com

Media Contact: Francesca Webb, +44(0)1865-843244, f.webb at elsevier.com